Article Details

Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti ... - PR Newswire

Retrieved on: 2022-09-27 19:47:55

Tags for this article:

Click the tags to see associated articles and topics

Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti ... - PR Newswire. View article details on HISWAI: https://www.prnewswire.com/news-releases/harbour-biomed-announces-first-subject-dosed-in-phase-i-study-of-next-gen-anti-tslp-fully-human-monoclonal-antibody-301634314.html

Excerpt

The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chains ( ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up